Mar 2, 2026, 08:24 AM by

Feb 26, 2026, 07:48 AM by

Epigenica has announced the launch of EpiFinder™ cNUC, a unique product for liquid biopsies that significantly expands the capabilities of epigenomic research by delivering deep insights directly from circulating nucleosomes.

Feb 26, 2026, 07:48 AM by

• Strengthens leadership team to support next phase of growth as organisation evolves to meet needs of global drug discovery community • Drs Gray and Duncan to lead scientific programmes and early career initiatives, respectively

Feb 26, 2026, 01:00 AM by User Not Found

Bio-IT World | Illumina completes its acquisition of SomaLogic; Sanofi appoints Belén Garijo as chief executive officer; Parse Biosciences launches the new Evercode Whole Transcriptome v4 product line; and more.

Feb 25, 2026, 08:02 AM by

Feb 25, 2026, 01:00 AM by User Not Found

Bio-IT World | Cellares expands across different countries to commercially launch and manufacture cell therapies; ILiAD Biotechnologies advances their next generation pertussis vaccine candidate, BPZE1; Galux develops next-gen AI that goes beyond binder design to incorporate functional activity and developability; and more.

Feb 24, 2026, 06:53 AM by

Inceptua Group announces the appointment of Kurt J. Hilzinger as Chairman of the Board.

Feb 24, 2026, 06:53 AM by

ClearNote Health announced an enhanced Avantect® Pancreatic Cancer Test, which delivers a higher overall cancer detection sensitivity of 82.6% and specificity of 97.5% for patients at elevated risk of this disease.

Feb 24, 2026, 06:53 AM by

Feb 24, 2026, 06:53 AM by

IDT’s NGS roadmap reflects a multi-omics strategy built on differentiated chemistries and algorithms that support DNA, methylation, and RNA sequencing workflows.

Feb 24, 2026, 01:01 AM by User Not Found

Bio-IT World | The Foundation for the National Institutes of Health (FNIH), Washington University in St. Louis, the University of California San Francisco, the University of Wisconsin-Madison, and more have published the results of a study in Nature Medicine that determined a blood-based biomarker model that estimates not only the likelihood of Alzheimer’s disease but also when symptoms are likely to emerge.

Feb 20, 2026, 01:01 AM by User Not Found

Bio-IT World | The scientific community has made tremendous progress in the ability to identify and predict protein targets, advancing from bulk cellular analysis approaches to technologies with resolutions that now approach subcellular. Despite these achievements, fundamental questions in drug discovery remain difficult to answer: has the ideal protein target been identified, and is it easily accessible to intervention to accelerate the development pipeline and reduce candidate attrition?

Feb 19, 2026, 01:00 AM by User Not Found

Bio-IT World | During the Clinical Trial Venture, Innovation, and Partnering event at this year’s SCOPE, Deloitte Consulting’s 2026 Life Sciences Executive Outlook revealed in a presentation that 75% of 280 surveyed C-suite executives across pharma and medtech expressed a positive or cautiously positive outlook. Yet beneath that headline lies a sharp transatlantic divide.

Feb 18, 2026, 20:49 PM by

Feb 18, 2026, 20:49 PM by

Specialized CRO has delivered 750 neuroscience studies advancing drug R&D with digital pathology

Feb 17, 2026, 01:00 AM by User Not Found

Bio-IT World | Repetitive head acceleration events (RHAEs) are repeated impacts that rapidly move the head and can cause concussions and brain damage. Yet current interventions remain reactive, focused on rest and symptom management after injury, rather than preventing microscopic damage that accumulates over time. A new study from the University of Utah Health has found an unconventional approach: photobiomodulation (PBM), or red light therapy.

Feb 13, 2026, 08:20 AM by

Feb 12, 2026, 11:44 AM by User Not Found

Bio-IT World | Anything that can be defined as a system—a mixed-bag list that includes physical materials like silicon and graphene as well as patient-specific implantable devices and the human brain—are subject to the law of entropy, meaning its disorder irreversibly increases over time if left alone. It turns out that this fundamental concept has a more comprehensive approach, dubbed zentropy by its creators at Penn State.

Feb 11, 2026, 01:01 AM by User Not Found

Bio-IT World | For decades, the industry’s approach to treating high blood pressure has centered on various organs—the heart, kidneys, and blood vessels. A new study suggests that this strategy may address downstream effects rather than the root cause. The primary driver of hypertension in a majority of patients may reside in the brain.

Feb 10, 2026, 09:45 AM by